Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.22
-0.09 (-0.68%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Stocks to Buy to Benefit From the Booming Sleep Industry
January 23, 2024
It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.
Via
InvestorPlace
Looking Into Takeda Pharmaceutical's Recent Short Interest
January 15, 2024
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 25, 2023
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 07, 2023
Via
Benzinga
Takeda Named Global Top Employer for Seventh Consecutive Year
January 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 16, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Peering Into Takeda Pharmaceutical's Recent Short Interest
November 21, 2023
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
November 03, 2023
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
One Ultra-Cheap High-Yield Dividend Stock to Buy
December 22, 2023
Now may be a good time for dividend investors to consider loading up on this stock.
Via
The Motley Fool
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
December 21, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
December 19, 2023
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...
Via
Benzinga
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
December 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
December 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
November 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Is Neurocrine Biosciences Stock Trading Lower Today?
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
November 10, 2023
The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:
Via
Benzinga
Exposures
Product Safety
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
November 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
November 07, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Earnings Scheduled For October 26, 2023
October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
Via
Benzinga
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
October 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
October 23, 2023
Analysts say Alkermes' drug is clearly active. But investors have concerns.
Via
Investor's Business Daily
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.